- Report
- April 2024
- 175 Pages
Global
From €4808EUR$5,000USD£4,124GBP
- Drug Pipelines
- January 2024
- 136 Pages
Global
From €7212EUR$7,500USD£6,187GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1442EUR$1,500USD£1,237GBP
- Report
- January 2024
- 178 Pages
Global
€4803EUR$4,995USD£4,120GBP
- Report
- July 2023
- 229 Pages
Global
From €4327EUR$4,500USD£3,712GBP
- Report
- December 2023
- 134 Pages
Global
From €3493EUR$3,633USD£2,997GBP
€4990EUR$5,190USD£4,281GBP
- Report
- February 2024
- 112 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Report
- January 2022
- 60 Pages
Global
From €3798EUR$3,950USD£3,258GBP
- Report
- March 2022
- 58 Pages
Global
From €3361EUR$3,495USD£2,883GBP
- Clinical Trials
- December 2019
- 154 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Drug Pipelines
- July 2020
- 98 Pages
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- October 2023
- 78 Pages
Global
From €3500EUR$3,899USD£3,108GBP
- Drug Pipelines
- March 2021
Global
From €1923EUR$2,000USD£1,650GBP
- Report
- September 2021
- 239 Pages
Global
From €5931EUR$6,168USD£5,088GBP
The Sarcopenia Drug market is a subset of the Musculoskeletal Disorders Drugs market, which focuses on the treatment of age-related muscle loss. Sarcopenia is a condition that affects older adults, causing a decrease in muscle mass, strength, and physical performance. Drugs used to treat sarcopenia are typically anabolic agents, such as testosterone, growth hormone, and selective androgen receptor modulators. These drugs are used to increase muscle mass and strength, as well as improve physical performance.
The Sarcopenia Drug market is expected to grow in the coming years due to the increasing prevalence of sarcopenia and the growing elderly population. Additionally, the development of new drugs and treatments for sarcopenia is expected to drive the market.
Some companies in the Sarcopenia Drug market include Pfizer, Merck, Novartis, Eli Lilly, and AbbVie. Show Less Read more
